Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers.

Eide K, Moerdyk-Schauwecker M, Stein DA, Bildfell R, Koelle DM, Jin L.

Antivir Ther. 2010;15(8):1141-9. doi: 10.3851/IMP1694.

PMID:
21149921
2.

Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27.

Moerdyk-Schauwecker M, Stein DA, Eide K, Blouch RE, Bildfell R, Iversen P, Jin L.

Antiviral Res. 2009 Nov;84(2):131-41. doi: 10.1016/j.antiviral.2009.07.020. Epub 2009 Aug 7.

PMID:
19665486
3.
4.
6.

In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus.

Deas TS, Bennett CJ, Jones SA, Tilgner M, Ren P, Behr MJ, Stein DA, Iversen PL, Kramer LD, Bernard KA, Shi PY.

Antimicrob Agents Chemother. 2007 Jul;51(7):2470-82. Epub 2007 May 7.

7.

Synthetic analogues of bovine bactenecin dodecapeptide reduce herpes simplex virus type 2 infectivity in mice.

Shestakov A, Jenssen H, Hancock RE, Nordström I, Eriksson K.

Antiviral Res. 2013 Nov;100(2):455-9. doi: 10.1016/j.antiviral.2013.08.019. Epub 2013 Sep 5.

PMID:
24012999
8.
10.

Genital herpes due to acyclovir-sensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient/temperature-sensitive virus.

Shimada Y, Suzuki M, Shirasaki F, Saito E, Sogo K, Hasegawa M, Takehara K, Phromjai J, Chuhjo T, Shiraki K.

J Med Virol. 2007 Nov;79(11):1731-40.

PMID:
17854045
11.

Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus.

Gabriel G, Nordmann A, Stein DA, Iversen PL, Klenk HD.

J Gen Virol. 2008 Apr;89(Pt 4):939-48. doi: 10.1099/vir.0.83449-0.

PMID:
18343835
12.

Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.

Pyles RB, Higgins D, Chalk C, Zalar A, Eiden J, Brown C, Van Nest G, Stanberry LR.

J Virol. 2002 Nov;76(22):11387-96.

13.

In vivo anti-herpes simplex virus activity of a sulfated derivative of Agaricus brasiliensis mycelial polysaccharide.

Cardozo FT, Larsen IV, Carballo EV, Jose G, Stern RA, Brummel RC, Camelini CM, Rossi MJ, Simões CM, Brandt CR.

Antimicrob Agents Chemother. 2013 Jun;57(6):2541-9. doi: 10.1128/AAC.02250-12. Epub 2013 Mar 18.

14.

Role of immediate early protein ICP27 in the differential sensitivity of herpes simplex viruses 1 and 2 to leptomycin B.

Park D, Lengyel J, Rice SA.

J Virol. 2013 Aug;87(16):8940-51. doi: 10.1128/JVI.00633-13. Epub 2013 Jun 5.

15.

Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.

Ziyaeyan M, Alborzi A, Japoni A, Kadivar M, Davarpanah MA, Pourabbas B, Abassian A.

Int J Dermatol. 2007 Dec;46(12):1263-6. doi: 10.1111/j.1365-4632.2007.03449.x.

PMID:
18173520
16.

Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner.

Huang WY, Su YH, Yao HW, Ling P, Tung YY, Chen SH, Wang X, Chen SH.

J Gen Virol. 2010 Mar;91(Pt 3):591-8. doi: 10.1099/vir.0.016964-0. Epub 2009 Nov 11.

PMID:
19906941
18.

Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells.

Faith SA, Sweet TJ, Bailey E, Booth T, Docherty JJ.

Antiviral Res. 2006 Dec;72(3):242-51. Epub 2006 Jul 14.

PMID:
16876885
19.

Activity of two synthetic amphiphilic peptides and magainin-2 against herpes simplex virus types 1 and 2.

Aboudy Y, Mendelson E, Shalit I, Bessalle R, Fridkin M.

Int J Pept Protein Res. 1994 Jun;43(6):573-82.

PMID:
7928088
20.
Items per page

Supplemental Content

Write to the Help Desk